Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
ESC Heart Failure|June 16, 2021
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trialSubodh Verma, Lawrence A Leiter, Bernard Zinman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 9, 2009
VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trialDuncan J Stewart, Michael J B Kutryk, David Fitchett, et al.
Circulation|December 28, 2018
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME TrialDavid Fitchett, Silvio E Inzucchi, Christopher P Cannon, et al.
Diabetes, Obesity & Metabolism|April 1, 2020
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trialSubodh Verma, Abhinav Sharma, Bernard Zinman, et al.
The American Journal of Cardiology|October 23, 2008
Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapyJennifer L Y Tsang, Aurora Mendelsohn, Mary K K Tan, et al.
American Heart Journal|February 7, 2012
Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trialShahar Lavi, Warren J Cantor, Amparo Casanova, et al.
The New England Journal of Medicine|September 18, 2015
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesBernard Zinman, Christoph Wanner, John M Lachin, et al.
The American Journal of Cardiology|August 14, 2014
Comparison of the efficacy of pharmacoinvasive management for ST-segment elevation myocardial infarction in smokers versus non-smokers (from the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction)Nigel S Tan, Shaun G Goodman, Warren J Cantor, et al.
Journal of Hypertension|July 4, 2020
Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOMEMichael Böhm, David Fitchett, Anne Pernille Ofstad, et al.
The Canadian Journal of Cardiology|June 26, 2016
Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)G B John Mancini, Steven Baker, Jean Bergeron, et al.
Pageof 10